|1.||Middleton, Steven A: 2 articles (10/2006 - 10/2005)|
|2.||Rugg, Catherine A: 2 articles (10/2006 - 10/2005)|
|3.||Emanuel, Stuart: 2 articles (10/2006 - 10/2005)|
|4.||Saio, M: 1 article (07/2012)|
|5.||Saitou, M: 1 article (07/2012)|
|6.||Hara, A: 1 article (07/2012)|
|7.||Shimizu, K: 1 article (07/2012)|
|8.||Matsuhashi, A: 1 article (07/2012)|
|9.||Kawai, G: 1 article (07/2012)|
|10.||Nagano, A: 1 article (07/2012)|
07/01/2012 - "JNJ-7706621 is a unique inhibitor regulating cell cycle progression at multiple points, suggesting that it could be useful for cell cycle analysis and therapy of various cancers, including Ewing's sarcoma."
10/01/2005 - "In human cancer cells, treatment with JNJ-7706621 inhibited cell growth independent of p53, retinoblastoma, or P-glycoprotein status; activated apoptosis; and reduced colony formation. "
06/15/2010 - "The aims of this work were (i) to formulate a novel CDK inhibitor, JNJ-7706621, in polymeric micelles and nanoparticles, (ii) to compare passive and active targeting on tumor growth and (iii) to evaluate the potential synergy of JNJ-7706621 with Paclitaxel. "
06/15/2010 - "Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621."
10/01/2005 - "JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases and selectively blocked proliferation of tumor cells of various origins but was about 10-fold less effective at inhibiting normal human cell growth in vitro. "
|2.||Ewing's Sarcoma (Sarcoma, Ewing)
|3.||Retinoblastoma (Glioblastoma, Retinal)
|1.||Cyclin-Dependent Kinases (cdk Proteins)
|2.||aurora kinase (aurora A kinase)
|1.||Heterologous Transplantation (Xenotransplantation)